Calprotectin-Directed Humira(R) Maintenance Therapy, a Double-blind, Double-dummy, Randomized Controlled Trial in Crohn's Disease
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 29 May 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms CADHUM
- 10 Jun 2017 Biomarkers information updated
- 10 May 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Jun 2013 Planned end date changed from 1 Sep 2013 to 1 Apr 2015 as reported by ClinicalTrials.gov.